| Douglas A Wolfe, MD | |
|
2500 North State Street, Department Of Medicine Division Of Cardiology, Jackson, MS 39216 | |
| (601) 984-5678 | |
| (601) 984-5638 |
| Full Name | Douglas A Wolfe |
|---|---|
| Gender | Male |
| Speciality | Cardiac Electrophysiology |
| Experience | 46 Years |
| Location | 2500 North State Street, Jackson, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861411621 | NPI | - | NPPES |
| 00117309 | Medicaid | MS |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Mississippi Med Center | Jackson, MS | Hospital |
| Wayne General Hospital | Waynesboro, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| State Of Mississippi - University Of Mississippi Medical Center | 1850293036 | 804 |
| Wayne General Hospital | 2668457581 | 38 |
News Archive
BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients.
InnerWireless®, Inc., the premier provider of end-to-end in-building converged wireless solutions, today reported that Spyglass Consulting Group's independent study of the new Critical Care Hospital at Virginia Commonwealth University Medical Center (VCU Medical Center) reveals the benefits of involving nursing staffs in the assessment and application of healthcare technologies such as InnerWireless' Horizon™ Converged Wireless solution.
A team of scientists with The Cancer Genome Atlas program reports their genetic characterization of 800 breast tumors, including finding some of the genetic causes of the most common forms of breast cancer, providing clues for new therapeutic targets, and identifying a molecular similarity between one sub-type of breast cancer and ovarian cancer.
Syneron Medical Ltd., a leading global aesthetic device company, announced today that it will host an investor meeting on Wednesday, September 17, 2014, at approximately 10:00 am to 1:00 pm ET in New York City. The meeting will highlight Syneron's opportunity in the fast growing body contouring and fat treatment market, with a focus on the UltraShape system, which received FDA clearance for fat cell destruction in April 2014.
› Verified 3 days ago
| Entity Name | Rush Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588625594 PECOS PAC ID: 2567368541 Enrollment ID: O20031210000541 |
News Archive
BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients.
InnerWireless®, Inc., the premier provider of end-to-end in-building converged wireless solutions, today reported that Spyglass Consulting Group's independent study of the new Critical Care Hospital at Virginia Commonwealth University Medical Center (VCU Medical Center) reveals the benefits of involving nursing staffs in the assessment and application of healthcare technologies such as InnerWireless' Horizon™ Converged Wireless solution.
A team of scientists with The Cancer Genome Atlas program reports their genetic characterization of 800 breast tumors, including finding some of the genetic causes of the most common forms of breast cancer, providing clues for new therapeutic targets, and identifying a molecular similarity between one sub-type of breast cancer and ovarian cancer.
Syneron Medical Ltd., a leading global aesthetic device company, announced today that it will host an investor meeting on Wednesday, September 17, 2014, at approximately 10:00 am to 1:00 pm ET in New York City. The meeting will highlight Syneron's opportunity in the fast growing body contouring and fat treatment market, with a focus on the UltraShape system, which received FDA clearance for fat cell destruction in April 2014.
› Verified 3 days ago
| Entity Name | Wayne General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093930638 PECOS PAC ID: 2668457581 Enrollment ID: O20040623000865 |
News Archive
BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients.
InnerWireless®, Inc., the premier provider of end-to-end in-building converged wireless solutions, today reported that Spyglass Consulting Group's independent study of the new Critical Care Hospital at Virginia Commonwealth University Medical Center (VCU Medical Center) reveals the benefits of involving nursing staffs in the assessment and application of healthcare technologies such as InnerWireless' Horizon™ Converged Wireless solution.
A team of scientists with The Cancer Genome Atlas program reports their genetic characterization of 800 breast tumors, including finding some of the genetic causes of the most common forms of breast cancer, providing clues for new therapeutic targets, and identifying a molecular similarity between one sub-type of breast cancer and ovarian cancer.
Syneron Medical Ltd., a leading global aesthetic device company, announced today that it will host an investor meeting on Wednesday, September 17, 2014, at approximately 10:00 am to 1:00 pm ET in New York City. The meeting will highlight Syneron's opportunity in the fast growing body contouring and fat treatment market, with a focus on the UltraShape system, which received FDA clearance for fat cell destruction in April 2014.
› Verified 3 days ago
| Entity Name | Laird Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821046798 PECOS PAC ID: 7214991769 Enrollment ID: O20050201000304 |
News Archive
BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients.
InnerWireless®, Inc., the premier provider of end-to-end in-building converged wireless solutions, today reported that Spyglass Consulting Group's independent study of the new Critical Care Hospital at Virginia Commonwealth University Medical Center (VCU Medical Center) reveals the benefits of involving nursing staffs in the assessment and application of healthcare technologies such as InnerWireless' Horizon™ Converged Wireless solution.
A team of scientists with The Cancer Genome Atlas program reports their genetic characterization of 800 breast tumors, including finding some of the genetic causes of the most common forms of breast cancer, providing clues for new therapeutic targets, and identifying a molecular similarity between one sub-type of breast cancer and ovarian cancer.
Syneron Medical Ltd., a leading global aesthetic device company, announced today that it will host an investor meeting on Wednesday, September 17, 2014, at approximately 10:00 am to 1:00 pm ET in New York City. The meeting will highlight Syneron's opportunity in the fast growing body contouring and fat treatment market, with a focus on the UltraShape system, which received FDA clearance for fat cell destruction in April 2014.
› Verified 3 days ago
| Entity Name | Yalobusha General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740380914 PECOS PAC ID: 4486601648 Enrollment ID: O20050331000530 |
News Archive
BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients.
InnerWireless®, Inc., the premier provider of end-to-end in-building converged wireless solutions, today reported that Spyglass Consulting Group's independent study of the new Critical Care Hospital at Virginia Commonwealth University Medical Center (VCU Medical Center) reveals the benefits of involving nursing staffs in the assessment and application of healthcare technologies such as InnerWireless' Horizon™ Converged Wireless solution.
A team of scientists with The Cancer Genome Atlas program reports their genetic characterization of 800 breast tumors, including finding some of the genetic causes of the most common forms of breast cancer, providing clues for new therapeutic targets, and identifying a molecular similarity between one sub-type of breast cancer and ovarian cancer.
Syneron Medical Ltd., a leading global aesthetic device company, announced today that it will host an investor meeting on Wednesday, September 17, 2014, at approximately 10:00 am to 1:00 pm ET in New York City. The meeting will highlight Syneron's opportunity in the fast growing body contouring and fat treatment market, with a focus on the UltraShape system, which received FDA clearance for fat cell destruction in April 2014.
› Verified 3 days ago
| Entity Name | Scott Regional Medical Center, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639367188 PECOS PAC ID: 0648366260 Enrollment ID: O20080423000448 |
News Archive
BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients.
InnerWireless®, Inc., the premier provider of end-to-end in-building converged wireless solutions, today reported that Spyglass Consulting Group's independent study of the new Critical Care Hospital at Virginia Commonwealth University Medical Center (VCU Medical Center) reveals the benefits of involving nursing staffs in the assessment and application of healthcare technologies such as InnerWireless' Horizon™ Converged Wireless solution.
A team of scientists with The Cancer Genome Atlas program reports their genetic characterization of 800 breast tumors, including finding some of the genetic causes of the most common forms of breast cancer, providing clues for new therapeutic targets, and identifying a molecular similarity between one sub-type of breast cancer and ovarian cancer.
Syneron Medical Ltd., a leading global aesthetic device company, announced today that it will host an investor meeting on Wednesday, September 17, 2014, at approximately 10:00 am to 1:00 pm ET in New York City. The meeting will highlight Syneron's opportunity in the fast growing body contouring and fat treatment market, with a focus on the UltraShape system, which received FDA clearance for fat cell destruction in April 2014.
› Verified 3 days ago
| Entity Name | State Of Mississippi - University Of Mississippi Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154317527 PECOS PAC ID: 1850293036 Enrollment ID: O20090414000575 |
News Archive
BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients.
InnerWireless®, Inc., the premier provider of end-to-end in-building converged wireless solutions, today reported that Spyglass Consulting Group's independent study of the new Critical Care Hospital at Virginia Commonwealth University Medical Center (VCU Medical Center) reveals the benefits of involving nursing staffs in the assessment and application of healthcare technologies such as InnerWireless' Horizon™ Converged Wireless solution.
A team of scientists with The Cancer Genome Atlas program reports their genetic characterization of 800 breast tumors, including finding some of the genetic causes of the most common forms of breast cancer, providing clues for new therapeutic targets, and identifying a molecular similarity between one sub-type of breast cancer and ovarian cancer.
Syneron Medical Ltd., a leading global aesthetic device company, announced today that it will host an investor meeting on Wednesday, September 17, 2014, at approximately 10:00 am to 1:00 pm ET in New York City. The meeting will highlight Syneron's opportunity in the fast growing body contouring and fat treatment market, with a focus on the UltraShape system, which received FDA clearance for fat cell destruction in April 2014.
› Verified 3 days ago
| Entity Name | Kemper Cah, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346546306 PECOS PAC ID: 5991985012 Enrollment ID: O20110622000294 |
News Archive
BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients.
InnerWireless®, Inc., the premier provider of end-to-end in-building converged wireless solutions, today reported that Spyglass Consulting Group's independent study of the new Critical Care Hospital at Virginia Commonwealth University Medical Center (VCU Medical Center) reveals the benefits of involving nursing staffs in the assessment and application of healthcare technologies such as InnerWireless' Horizon™ Converged Wireless solution.
A team of scientists with The Cancer Genome Atlas program reports their genetic characterization of 800 breast tumors, including finding some of the genetic causes of the most common forms of breast cancer, providing clues for new therapeutic targets, and identifying a molecular similarity between one sub-type of breast cancer and ovarian cancer.
Syneron Medical Ltd., a leading global aesthetic device company, announced today that it will host an investor meeting on Wednesday, September 17, 2014, at approximately 10:00 am to 1:00 pm ET in New York City. The meeting will highlight Syneron's opportunity in the fast growing body contouring and fat treatment market, with a focus on the UltraShape system, which received FDA clearance for fat cell destruction in April 2014.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Douglas A Wolfe, MD 2500 N State St, Dept Of Medicine/division Of Cardiology, Jackson, MS 39216-4500 Ph: (601) 984-5678 | Douglas A Wolfe, MD 2500 North State Street, Department Of Medicine Division Of Cardiology, Jackson, MS 39216 Ph: (601) 984-5678 |
News Archive
BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients.
InnerWireless®, Inc., the premier provider of end-to-end in-building converged wireless solutions, today reported that Spyglass Consulting Group's independent study of the new Critical Care Hospital at Virginia Commonwealth University Medical Center (VCU Medical Center) reveals the benefits of involving nursing staffs in the assessment and application of healthcare technologies such as InnerWireless' Horizon™ Converged Wireless solution.
A team of scientists with The Cancer Genome Atlas program reports their genetic characterization of 800 breast tumors, including finding some of the genetic causes of the most common forms of breast cancer, providing clues for new therapeutic targets, and identifying a molecular similarity between one sub-type of breast cancer and ovarian cancer.
Syneron Medical Ltd., a leading global aesthetic device company, announced today that it will host an investor meeting on Wednesday, September 17, 2014, at approximately 10:00 am to 1:00 pm ET in New York City. The meeting will highlight Syneron's opportunity in the fast growing body contouring and fat treatment market, with a focus on the UltraShape system, which received FDA clearance for fat cell destruction in April 2014.
› Verified 3 days ago
Graves Crawley Stubblefield Jr., M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 406 Briarwood Dr, Jackson, MS 39206 Phone: 601-991-1933 Fax: 601-978-3844 | |
Dr. Rebecca Chick Pace, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1200 N State St, Suite 500, Jackson, MS 39202 Phone: 601-352-2273 Fax: 601-714-3415 | |
Jewelian Akbar Baig, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 971 Lakeland Dr Ste 356, Jackson, MS 39216 Phone: 601-200-4644 Fax: 601-200-4645 | |
Jo P Deal, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 766 Lakeland Dr # A, Jackson, MS 39216 Phone: 601-368-3440 Fax: 601-368-3441 | |
Caryl P. Sumrall, FNP Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2500 North State Street, Department Of Medicine/division Of General Internal Med, Jackson, MS 39216 Phone: 601-984-5660 | |
Meghan Alford Luter, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 N State St, Jackson, MS 39216 Phone: 601-984-5532 | |
Tammy H Young, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1227 N State St, Ste 101, Jackson, MS 39202 Phone: 601-355-2485 Fax: 601-353-1463 |